American pharmaceutical company Pfizer, which has developed a vaccine for coronavirus in association with BioNTech of Germany, has claimed that its vaccine is going though the third phase of trial and will be 90 percent effective in preventing the deadly virus.

The fresh cases of COVID-19 are rising all across the globe. The intensive care units of the hospitals are filling up fast and the death toll is mounting worldwide.

For the prevention against COVID-19, a human would require two dosage of the vaccine. The preliminary findings of the human trials show that complete protection can be achieved in 28 days after the first dose and seven days after the second one.

“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” Pfizer chairman and CEO Albert Bourla stated.

“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most,” he added.

Pfizer and BioNTech are planning to supply close to 50 million doses of the vaccines before the end of 2020 and close to 1.3 billion doses in the next year.

United States’ Moderna and University of Oxford-AstraZeneca are among the other potential vaccine candidates, besides some state-run Chinese laboratories. Russia has registered two vaccines even before they could reach the clinical trials. None of the two vaccines has been accepted outside of Russia.

“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks,” Bourla said.